-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Special Scientific Session on Race and Science: Bench to Bedside to the Community

PhD Trainee
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Clinical Practice (Health Services and Quality), Translational Research, Clinical Research, Diversity, Equity, and Inclusion (DEI)
Sunday, December 10, 2023: 9:30 AM-11:00 AM
Hall A (San Diego Convention Center)

Lecture Title:
“Race and Science: Bench to Bedside to the Community

Elizabeta Nemeth, PhD, David Geffen School of Medicine At UCLA , Alison R. Walker, MD, MPH, MBA, H.Lee Moffitt Cancer Center & Research Institute and Nadine J Barrett, PhD, MS, MA, Wake Forest University School of Medicine
Barrett: GSK: Speakers Bureau.
Race is a prominent focus in academic health centers in the country, but what role do racial categories play in biomedical research or in the delivery of care to patients? Disparities in health care and disease outcomes exist, and there are racial groups who experience disproportionally worse outcomes and a shortened life expectancy. However, racial categories, as designed, represent social and biological factors that are not fully understood. How might we utilize race more appropriately – not to discriminate but to better understand the biology of disease while also delivering equitable care? This session is intended to serve as both the foundation and the beginning of a conversation on these critical issues.Each speaker will present different perspectives on how and where to begin this discussion.  

Dr. Alisa Wolberg will discuss the role of the basic scientist and how the concepts of diversity, equity, and inclusion may be considered when designing investigations and experiments that will lead to data that is broadly generalizable and applicable.  

Dr. Saad Usmani will address the next step, regarding moving basic science to the bedside and discussing strategies that assure clinical trials with novel therapies are inclusive and diverse.  

Ms. Shonta Chambers will provide the patient perspective and will highlight how best to engage with community and national organizations to strengthen the relationship between patients and the health care team to achieve the goal of equitable access to care and innovation. 

Dr. Nicole Gormley will present on the US Food and Drug Administration’s guidance on “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.” She will highlight the potential impact that regulatory agencies may have on clinical trial development. 

Shonta Chambers, MSW

Patient Advocate Foundation, Hampton, VA

Saad Z Usmani, MD

Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Nicole Gormley, MD

Division of Hematologic Malignancies II, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD

Alisa S Wolberg, PhD

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC